|
|
||||||||
Published online before print February 20, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
1 Correspondence at current address: Max-Delbruck-Center for Molecular Medicine, Robert-Rossle-Strasse 10, 13092, Berlin, Germany. E-mail: j.charo{at}mdc-berlin.de
There have been disparate findings about the role of FLIP in the survival of mouse T cells and human tumor cell lines. The role of cellular FLIP in human T cell activation and function needs to be clarified further. To study this role, we have overexpressed long transcript FLIP (FLIPL) in primary T cells, including self-antigen-reactive, melanoma-specific T cells. We found that FLIPL overexpression protects human T cells from activation-induced cell death and enhances their prolifertive capacity but suppresses the ability of these cells to produce the proinflammatory cytokines IL-2 and IFN-
in response to CD3 or antigen-specific stimulation. The multiple effects of FLIPL indicate that this protein may influence T cell responses to antigenic stimulation.
Key Words: tumor autoimmunity apoptosis cellular activation tolerance
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |